Postpartum experiences among individuals with suspected and confirmed prenatal generalized anxiety disorder during the COVID-19 pandemic: Implications for help-seeking. (May 2023)

• Record Type: Journal Article
• Authors: Koire, Amanda; Feldman, Natalie; Erdei, Carmina; Mittal, Leena; Liu, Cindy H.
• Is Part Of: Psychiatry research. Volume 323(2023)
• Publication Date: 2023-05
• Subjects: Postpartum -- Anxiety -- Depression -- COVID-19 -- Distress tolerance -- Resilience; Psychiatry -- Periodicals; Psychiatry -- periodicals; Psychiatrie -- Périodiques; 616.89
• DOI: 10.1016/j.psychres.2023.115169
• Languages: English
• ISSNs: 0165-1781

Abstract

Highlights: Generalized Anxiety Disorder during pregnancy affected 23% of pregnant individuals. Untreated GAD in pregnancy experienced highest levels of postpartum mood disturbance. Treated GAD in pregnancy showed postpartum mood similar to no prenatal GAD diagnosis. Universal screening for GAD during pregnancy should be considered. Abstract: Prenatal generalized anxiety disorder (GAD) is a common and underdiagnosed condition with negative health consequences to both the pregnant individual and child. Here we studied the relationship between diagnosis and treatment status of GAD during pregnancy (no GAD diagnosis, suspected but not diagnosed, diagnosed but not treated, diagnosed and treated) during the COVID-19 pandemic and postpartum mental health outcomes, while considering the potential influence of individual psychological factors such as distress tolerance and resilience and the role of COVID-19-related health worries. In this sample of predominantly highly educated and white birthing individuals, one in five respondents experienced GAD during pregnancy and another one in six suspected GAD but was not diagnosed. Amongst those with a GAD diagnosis, 30% did not receive treatment. We found that those with a GAD diagnosis during pregnancy who did not receive treatment showed the highest levels of postpartum anxiety and depressive symptoms in the postpartum, even after controlling for covariates, and experienced the most COVID-19-related health worries. In comparison, individuals with a GAD diagnosis during pregnancy who received treatment experienced significantly lower anxiety symptom burden and depressive symptom burden, with a symptom burden similar to those without a confirmed or suspected diagnosis after controlling for individual psychological factors. We conclude that clinicians should strongly consider screening for and treating prenatal anxiety to prevent suboptimal postpartum mental health outcomes.